Evidence & Research Status
A compounded peptide, a research peptide, and an FDA-approved drug can all share the same molecular name — and still occupy three entirely different legal and evidentiary categories. As mainstream…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
A compounded peptide, a research peptide, and an FDA-approved drug can all share the same molecular name — and still occupy three entirely different legal and evidentiary categories. As mainstream coverage of the FDA’s July 2026 peptide advisory votes grows, that distinction is getting blurred in exactly the way that leads to confusion, and occasionally to warning letters.
Four Questions, Not One
When someone asks “is this peptide legal?” or “is this peptide safe?”, they’re usually really asking four separate questions at once. Keeping them separate is the single most useful mental model for navigating this space:
| Status | What It Actually Answers |
|---|---|
| Research status | Is the substance being actively studied, and is it sold as a laboratory/research material rather than a consumer drug? |
| Compounding status | May a licensed 503A or 503B pharmacy legally prepare this substance for a patient under a prescription? |
| FDA approval status | Has FDA evaluated and approved a specific drug, formulation, and indication through the full drug-approval process? |
| Evidence status | How strong is the human clinical evidence for the specific use being discussed? |
These four are related, but none of them substitutes for the others. A compounded peptide is not automatically FDA-approved. A prescription does not certify that a drug has completed FDA safety review. Research status does not mean a substance is unregulated. And none of the above says anything about whether the evidence for a specific claimed use is strong, weak, or nonexistent.
Why “Compounded” Doesn’t Mean “Approved”
FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting evaluated whether BPC-157, KPV, TB-500, MOTS-c, Semax, DSIP/emideltide, and Epitalon meet the criteria for the 503A Bulk Drug Substances List — the list that determines whether a licensed compounding pharmacy may legally prepare a substance for a patient. A favorable committee vote on that list is a recommendation about pharmacy compounding eligibility. It is not, and has never been, an FDA drug approval. FDA has stated it is still considering the committee’s recommendations and has not issued a final decision on any of the seven substances discussed. For the specific vote counts and current status of each compound, see our ongoing coverage of the July PCAC meeting.
Retatrutide and cagrilintide sit in a different category entirely. FDA has stated that both are not currently eligible for compounding under federal law, are not components of an FDA-approved drug, and have not been found safe and effective for any condition. Mainstream coverage describing either compound as a coming successor to existing GLP-1 drugs is describing investigational, unapproved compounds — not a product with an established legal compounding or approval pathway.
Where Research Peptides Fit
A research peptide sold for laboratory or research use is a third category again. It is not sold, marketed, or labeled as a drug for human consumption, is not dispensed under a prescription, and makes no claim to have completed FDA review. That’s a narrower, more conservative position than either compounding or approval — and it’s the position Portal to Wellness operates from for every product in the catalog.
Why This Distinction Is Suddenly Getting More Scrutiny
Recent mainstream reporting has shifted from covering individual peptide vote totals toward asking a bigger question: could the 503A pathway be used to commercialize compounds at scale before they’ve cleared the evidence bar that FDA drug approval normally requires? Critics point to limited human safety data, oversight gaps at the pharmacy level, and the risk that consumers mistake compounding eligibility for official validation. Supporters counter that regulated compounding, done well, could be safer than unsupervised gray-market purchasing. Both sides of that debate are really arguing about the gap between compounding status and evidence status — which is exactly why keeping the four categories separate matters more now than it did a year ago.
A Practical Test Before Repeating Any Claim
Before treating any statement about a peptide as settled, it’s worth asking: which of the four categories is this claim actually about? “It’s under FDA review” is a compounding-status claim. “My prescriber gave it to me” says nothing about FDA approval. “There’s promising research” is an evidence-status claim, not a legal one. And “it’s sold for research use” is neither an approval nor a safety claim — it’s a narrower, specific description of how and why a product is being sold.
Open Questions for Researchers
Several things remain genuinely unresolved. Will FDA’s eventual final action on the seven reviewed peptides track the PCAC’s recommendations, or diverge from them the way FDA staff’s own briefing documents suggested it might? If compounding eligibility expands, will evidence requirements for specific claimed uses (like tendon repair or general recovery) be clarified, or will that gap persist? And how should consumers and researchers verify testing and sourcing when a compound’s legal category is still in flux? None of these have firm answers yet — which is itself useful information.
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.